Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9834571B2 · kind B2 · utility
2Cited by
50References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 16, 2016 |
| Grant date | Dec 5, 2017 |
| Priority date | — |
| Expiry date | Feb 16, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65846
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I:wherein the variables are as defined herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.